In recent months, Keros Therapeutics, Inc. has made significant strides in its clinical research endeavors, focusing on the modulation of the transforming growth factor-beta (TGF-β) signaling pathway. This pathway has been implicated in a variety of disorders, and Keros has targeted its therapeutic development towards conditions such as pulmonary arterial hypertension (PAH), myelodysplastic syndromes (MDS), and obesity.
On September 3, 2024, Keros announced the closure of screening for the Phase 2 TROPOS trial, which evaluates the efficacy of cibotercept (KER-012) in combination with standard background therapy for patients diagnosed with PAH. The trial has progressed to a stage where Keros anticipates completing enrollment by the end of September 2024, with an expected presentation of topline results in the second quarter of 2025. The TROPOS trial represents a critical advancement in the field of PAH treatment, aiming to address a condition characterized by elevated blood pressure in the pulmonary arteries, leading to significant morbidity and mortality.
In a prior announcement on March 14, 2024, Keros received Fast Track designation from the U.S. Food and Drug Administration (FDA) for KER-050 (elritercept) aimed at treating anemia in adult patients with very low-, low-, or intermediate-risk MDS. The designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. This recognition underscores the potential of KER-050 to improve patient outcomes related to MDS, a group of hematologic disorders that disrupt normal bone marrow function, resulting in reduced production of blood cells.
Moreover, as of January 3, 2024, Keros announced its intentions to develop KER-065, a ligand trap engineered to bind and inhibit TGF-β ligands, including myostatin (GDF8) and activin A. This approach may offer promising therapeutic options for obesity, a complex and multifactorial disease that poses significant health risks globally.
Keros Therapeutics’ commitment to addressing disorders linked to dysfunctional TGF-β signaling is evident in its robust pipeline of investigational therapies. With ongoing clinical trials and regulatory accomplishments, Keros is poised to make meaningful contributions to the treatment landscape for PAH, MDS, and obesity, potentially improving the quality of life for affected patients and altering the course of these diseases. The anticipated results from the TROPOS trial and the further development of KER-050 and KER-065 will be closely watched by both clinicians and patients alike as Keros moves forward in its mission to develop novel therapeutics in these challenging therapeutic areas.
Comments